Latanoprost , 10mMinDMSO , 130209-82-4

Synonym(s):
Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate;Isopropyl (5Z,9α,11α,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate;Latanoprost;Xalatan

CAS NO.：130209-82-4

Empirical Formula: C26H40O5

Molecular Weight: 432.59

MDL number: MFCD00216074

EINECS: 634-172-9

PRODUCT Properties

• alpha: D20 +31.57° (c = 0.91 in acetonitrile)
• Boiling point: 583.8±50.0 °C(Predicted)
• Density: 1.093±0.06 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: DMSO: freely soluble
• form: oil
• pka: 14.84±0.70(Predicted)
• color: pale yellow
• Merck: 14,5376
• BCS Class: 2
• InChIKey: GGXICVAJURFBLW-RDSJPUOVSA-N

Description and Uses

Xalatan was launched in Sweden, Switzerland and the US for the treatment of glaucoma. It can be synthesized, from the Corey lactone, using standard prostaglandin chemistry. Latanoprost is a PGF_2α, analog that is more lipophilic thus is better able to penetrate the cornea. The (15R)-diastereomer has only 10% of the activity compared to the (15S)-diastereomer. It is a selective FP receptor agonist with little or no effect on the other prostanoid receptors. The antiglaucoma effects are the result of reduced intraocular pressure arising by increasing uveoscleral outflow with little or no effect on trabeculo-canalicular aqueous outflow and no effect on retinal vasculation or permeability of the blood-aqueous barrier. The topical application is sufficient for a single daily dosage and is well tolerated with no detectible conjunctival hyperaemia.

antifungal polyene macrolide that is active in the cell membrane soluble 5% Acetic acid

Safety

• Symbol(GHS): GHS05,GHS08
• Signal word: Warning
• Hazard statements: H413
• Precautionary statements: P501-P273
• WGK Germany: 3
• RTECS: MJ9669550
• HS Code: 2937500000